Differential regulation of p21waf1 protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 1047-1057

  Chang, Li Ju ^a,b   Eastman, Alan ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cell cycle arrest; Chk1; DNA damage; Nutlin 3; p21waf1; p53

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; CYCLIN DEPENDENT KINASE INHIBITOR 1; FIRTECAN; MK 8776; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN INDUCTION; TRANSCRIPTION REGULATION;

CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IMIDAZOLES; PIPERAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865840231     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21047     Document Type: Article

References (49)

1. Massagué J. G1 cell cycle control and cancer. Nature 2004; 432:298-306; PMID:15549091; http://dx.doi.org/10.1038/nature03094.
2. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 2010; 29:6085-98; PMID:20818418; http://dx.doi.org/10.1038/onc.2010.407.
3. Kastan MB, Bartek J. Cell cycle checkpoints and cancer. Nature 2004; 432:316-23; PMID:15549093; http://dx.doi.org/10.1038/nature03097.
4. Rudolph J. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nat Rev Cancer 2007; 7:202-11; PMID:17287826; http://dx.doi.org/10.1038/nrc2087.
5. Aylon Y, Oren M. New plays in the p53 theater. Curr Opin Genet Dev 2011; 21:86-92; PMID:21317061; http://dx.doi.org/10.1016/j.gde.2010.10.002.
6. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-8; PMID:18231106; http://dx.doi.org/10.1038/sj.bjc.6604208.
7. Kuntz K, O'Connell MJ. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther 2009; 8:1433-9; PMID:19574738; http://dx.doi.org/10.4161/cbt.8.15.9081.
8. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13:1955-60; PMID:17404075; http://dx.doi.org/10.1158/1078-0432.CCR-06-2793.
9. Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH, et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 2002; 1:1067-78; PMID:12481430.
10. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002; 277:26553-64; PMID:11953432; http://dx.doi.org/10.1074/jbc.M202040200.
11. Chang LJ, Eastman A. Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors. Cell Cycle 2012; 11:1818-26; PMID: 22510560; http://dx.doi.org/10.4161/cc/20208.
12. Levesque AA, Fanous AA, Poh A, Eastman A. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther 2008; 7:252-62; PMID:18281511; http://dx.doi.org/10. 1158/1535-7163.MCT-07-2066.
13. Eastman A. The importance of p53 signaling in the response of cells to checkpoint inhibitors. In: Siddik ZH, (Ed). Checkpoint Controls and Targets in Cancer Therapy. Humana Press 2010; 189-98.
14. Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, et al. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell 2011; 43:57-71; PMID:21726810; http://dx.doi.org/10.1016/j. molcel.2011.06.012.
15. Pochampally R, Fodera B, Chen L, Lu W, Chen J. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J Biol Chem 1999; 274:15271-7; PMID:10329737; http://dx.doi.org/10.1074/jbc.274.21.15271.
16. Pochampally R, Fodera B, Chen L, Shao W, Levine EA, Chen J. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 1998; 17:2629-36; PMID:9840926; http://dx.doi.org/10.1038/sj.onc.1202206.
17. Chen L, Marechal V, Moreau J, Levine AJ, Chen J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J Biol Chem 1997; 272:22966-73; PMID:9278461; http://dx.doi.org/10.1074/jbc.272.36.22966.
18. Bartel F, Harris LC, Würl P, Taubert H. MDM2 and its splice variant messenger RNAs: expression in tumors and downregulation using antisense oligonucleotides. Mol Cancer Res 2004; 2:29-35; PMID:14757843.
19. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002; 2:9-15; PMID:12150820; http://dx.doi.org/10.1016/S1535-6108(02)00091-0.
20. Gottifredi V, Karni-Schmidt O, Shieh SS, Prives C. p53 downregulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol 2001; 21:1066-76; PMID:11158294; http://dx.doi.org/10.1128/MCB.21.4.1066-76.2001.
21. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 2002; 99:14795-800; PMID:12399544; http://dx.doi.org/10.1073/pnas.182557299.
22. Jin Y, Lee H, Zeng SX, Dai MS, Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 2003; 22:6365-77; PMID:14633995; http://dx.doi.org/10.1093/emboj/cdg600.
23. Xu H, Zhang Z, Li M, Zhang R. MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem 2010; 285:18407-14; PMID:20308078; http://dx.doi.org/10.1074/jbc.M109.059568.
24. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 2004; 279:16000-6; PMID:14761977; http://dx.doi.org/10.1074/jbc.M312264200.
25. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 2003; 22:2036-46; PMID:12727871; http://dx.doi.org/10.1093/emboj/cdg189.
26. Jin Y, Zeng SX, Sun XX, Lee H, Blattner C, Xiao Z, et al. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol Cell Biol 2008; 28:1218-29; PMID:18086887; http://dx.doi.org/10.1128/MCB.01198-07.
27. Xu S, Feng Z, Zhang M, Wu Y, Sang Y, Xu H, et al. hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene 2011; 30:2219-29; PMID:21242961; http://dx.doi.org/10.1038/onc.2010.596.
28. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther 2012; 11:427-38; PMID:22203733; http://dx.doi.org/10.1158/1535-7163.MCT-11-0406.
29. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216-25; PMID:14993903; http://dx.doi.org/10.1038/nrc1296.
30. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49:223-41; PMID:18834305; http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094723.
31. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103:1888-93; PMID:16443686; http://dx.doi.org/10.1073/pnas.0507493103.
32. Lee H, Zeng SX, Lu H. UV Induces p21 rapid turnover independently of ubiquitin and Skp2. J Biol Chem 2006; 281:26876-83; PMID:16803887; http://dx.doi.org/10.1074/jbc.M605366200.
33. Stuart SA, Wang JY. Ionizing radiation induces ATM-independent degradation of p21Cip1 in transformed cells. J Biol Chem 2009; 284:15061-70; PMID:19332548; http://dx.doi.org/10.1074/jbc.M808810200.
34. Menendez JA, Mehmi I, Lupu R. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Int J Oncol 2005; 26:649-59; PMID:15703820.
35. Nam M, Lee WH, Bae EJ, Kim SG. Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition. Arch Biochem Biophys 2008; 479:74-81; PMID:18721791; http://dx.doi.org/10.1016/j.abb. 2008.07.029.
36. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002; 62:6901-8; PMID:12460905.
37. Luo XJ, Li W, Yang LF, Yu XF, Xiao LB, Tang M, et al. DAPK1 mediates the G1 phase arrest in human nasopharyngeal carcinoma cells induced by grifolin, a potential antitumor natural product. Eur J Pharmacol 2011; 670:427-34; PMID:21914449; http://dx.doi.org/10.1016/j.ejphar.2011.08.026.
38. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/nrm2395.
39. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20:3224-33; PMID:10757806; http://dx.doi.org/10.1128/MCB.20.9.3224-33.2000.
40. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36:131-49; PMID:12814430; http://dx.doi.org/10.1046/j.1365-2184.2003.00266.x.
41. Valentine JM, Kumar S, Moumen A. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer 2011; 11:79; PMID:21338495; http://dx.doi.org/10.1186/1471-2407-11-79.
42. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004; 279:53015-22; PMID:15471885; http://dx.doi.org/10.1074/jbc.M410233200.
43. Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C. DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 2010; 79:565-74; PMID:19788889; http://dx.doi.org/10.1016/j.bcp.2009.09.020.
44. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105:3933-8; PMID:18316739; http://dx.doi.org/10.1073/pnas.0708917105.
45. Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S, et al. p21(WAF1/CIP1) mediates the growth response to TGFbeta in human epithelial cells. Cancer Biol Ther 2004; 3:221-5; PMID:14726675; http://dx.doi.org/10.4161/ cbt.3.2.666.
46. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-90; PMID:7585571.
47. Demarcq C, Bunch RT, Creswell D, Eastman A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 1994; 5:983-93; PMID:7819136.
48. Rago R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem 1990; 191:31-4; PMID:1706565; http://dx.doi.org/10.1016/ 0003-2697(90)90382-J.
49. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:45; PMID:11328886; http://dx.doi.org/10.1093/nar/29.9.e45.